The US FDA's approval of a cardiovascular risk reduction claim for Novo Nordisk AS' GLP-1 agonist Victoza (liraglutide) for patients with type 2 diabetes and established cardiovascular disease reflects an advisory committee's discomfort with the broader, primary prevention claim requested by the sponsor.
On Aug. 25, FDA approved Novo's supplemental new drug application (sNDA) to reduce the risk of major adverse cardiovascular events...






